Hypertriglyceridemia in bone marrow transplant recipients: another side effect of cyclosporine A.
The incidence and duration of hypertriglyceridemia (HTG) associated with allogeneic HLA-identical bone marrow transplantation (BMT) were investigated in 38 patients with normal triglyceride levels (TG) before BMT and without any evidence of prior liver disorder. Twenty-two (58%) patients developed HTG. The median of TG peak values was 350 mg/dl (range 215-908) and the median actuarial time for HTG appearance was 7 weeks (range 1-12). Among several variables analysed (age, sex, hyperglycemia, total parenteral nutrition, treatment with methylprednisolone, estrogens or cyclosporine A) only cyclosporine A administration was significantly associated with HTG development.
Carreras
E
E
Postgraduate School of Haematology, Farreras Valenti Hospital Clínic, University of Barcelona, Spain.
Villamor
N
N
Reverter
J C
JC
Sierra
J
J
Grañena
A
A
Rozman
C
C
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006648:Histocompatibility; D006801:Humans; D015228:Hypertriglyceridemia / Q000209:etiology* / Q000473:pathology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D014184:Transplantation, Homologous
D003524:Cyclosporins; D006680:HLA Antigens; D007166:Immunosuppressive Agents